Overview

101-PGC-005 for the Treatment of COVID-19

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of hospitalized patients with coronavirus disease (COVID-19).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

101 Therapeutics

Treatments:

Dexamethasone